Glial Connexin-43 is a pathogenic mechanism promoting gut inflammation after postsurgical intestinal manipulation with potential relevance to humans.

Summary

This mechanistic study shows that enteric glial connexin-43 is upregulated after surgical intestinal manipulation and drives inflammation, immune activation, and neuropathy underlying postoperative ileus. Genetic deletion or peptide inhibition (43Gap26) of glial Cx43 dampened pro-inflammatory signaling and protected against POI features, with supportive signals observed in human surgical tissue and human enteric glial cells.

Key Findings

• Cx43 is the highest-expressed connexin in enteric glia in mice and humans and is upregulated after surgical trauma and in POI-related models.
• Glial Cx43 deletion reduced glial reactivity, pro-inflammatory signaling, immune cell activation, and prevented enteric neuropathy in a mouse POI model.
• IL-1β opened Cx43 hemichannels in human enteric glial cells, increasing IL-6 and CCL2 release; the peptide inhibitor 43Gap26 blocked these responses.
• Patient intestinal trauma samples showed Cx43 upregulation paralleling mouse POI inflammation and enteric gliosis.

Clinical Implications

Blocking glial Cx43 signaling could prevent or mitigate postoperative ileus; perioperative trials of Cx43 modulators or repurposed gap junction inhibitors may be warranted, alongside biomarker development for enteric gliosis.

Limitations

• Predominantly preclinical evidence; clinical efficacy of Cx43 inhibitors for POI remains untested
• Quantitative human sample sizes and longitudinal clinical outcomes were not detailed

Future Directions

Develop selective, clinically viable Cx43 hemichannel modulators; test efficacy and safety in large animal models and early-phase perioperative trials with gliosis/inflammation biomarkers.